News | Radiation Therapy | January 31, 2018

Varian Signs Agreement to Acquire Sirtex

Acquisition adds Sirtex’s SIR-Spheres Y-90 resin microspheres to Varian’s interventional oncology portfolio

Varian Signs Agreement to Acquire Sirtex

January 31, 2018 — Varian Medical Systems announced it has signed an agreement to acquire all the outstanding shares of Sirtex Medical Ltd., an Australia-based global life sciences company focused on interventional oncology therapies. Sirtex is listed on the Australian Securities Exchange, for A$28 per share in cash. On a fully diluted basis, this represents a total equity purchase price for the acquisition of approximately A$1,585M (approximately US$1,283M). The acquisition has been unanimously approved by the Board of Directors of each company and the Sirtex Board of Directors has agreed to unanimously recommend that Sirtex shareholders approve the transaction, provided that an independent expert, to be retained by Sirtex, considers the transaction to be in the best interests of Sirtex shareholders and in the absence of a superior offer.

Varian said the acquisition of Sirtex, which specializes in radioembolization, expands Varian's addressable market into interventional oncology. Varian expects to leverage its capabilities in treatment planning and delivery, image guidance and processing, oncology practice management software, and radiation safety in combination with Sirtex's interventional oncology platform.

Sirtex's lead product is a targeted internal radiation therapy for certain liver cancers. Approximately 80,000 doses of SIR-Spheres Y-90 resin microspheres have been supplied to treat patients with liver cancer at more than 1,090 medical centers in over 40 countries. It has premarket approval (PMA) from the U.S. Food & Drug Administration (FDA), the European Union (CE Mark) and Australia's Therapeutic Goods Administration (TGA). Sirtex has manufacturing capabilities in the United States, Singapore and Germany.

Sirtex generated annual revenues of A$234mm in the fiscal year ended June 30, 2017. Sirtex has approximately 300 employees worldwide and maintains sales and distribution operations primarily in the United States, Europe and Asia.

For more information: www.varian.com, www.sirtex.com

 

Related Content

Videos | Radiation Therapy | August 13, 2018
ITN Editor Dave Fornell takes a tour of some of the innovative new technologies on the expo floor at the 2018 America
Videos | Radiation Therapy | August 13, 2018
A discussion with Mahadevappa Mahesh, MS, Ph.D., FAAPM, FACR, FACMP, FSCCT, professor of radiology and cardiology and
Videos | Proton Therapy | August 10, 2018
A discussion with Matthew Freeman, Ph.D., scientist at Los Alamos National Laboratory, New Mexico.
Videos | Radiomics | August 09, 2018
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada.
Videos | AAPM | August 03, 2018
Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke Un...
Videos | Artificial Intelligence | August 01, 2018
A discussion with Steve Jiang, Ph.D., director of the medical...
Videos | Radiation Therapy | August 01, 2018
This is an example of how Cherenkov radiation glow can be collected with image intensifier cameras during radiotherap
Videos | AAPM | August 01, 2018
American Association of Physicists in Medicine (AAPM) President Bruce Thomadsen, M.D., professor of medical physics a
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
Overlay Init